The US Food and Drug Administration (FDA) on Friday approved retinal disease specialist Apellis Pharmaceuticals' (Nasdaq: APLS) drug for geographic atrophy secondary to age-related macular degeneration (AMD) after pushing back its planned decision by three months to review more data.
Under the trade name Syfovre, pegcetacoplan injection becomes the first and only FDA-approved treatment for GA, a leading cause of blindness that impacts more than one million people in the USA and five million people worldwide.
Apellis shares closed up almost 7%, and rose a further 9.3% to $60.67 in after-hours trading.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze